Compare Somnigroup International Inc. Common Stock (SGI) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Somnigroup International Inc. Common Stock vs Vertex Pharmaceuticals Incorporated — how do they compare? Somnigroup International Inc. Common Stock trades at $62.78 (market cap $14.48B), while Vertex Pharmaceuticals Incorporated trades at $504.96 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 8.5× Somnigroup International Inc. Common Stock's market cap, and Somnigroup International Inc. Common Stock pays a 1.08% dividend while Vertex Pharmaceuticals Incorporated pays none. Which is the better fit depends on your goals — on Pluang, investors hold Somnigroup International Inc. Common Stock for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| SGI | VRTX | |
|---|---|---|
Market Cap | $14.48B | $122.98B |
Volume | 1,734,399 | 1,155,743 |
Sector | Consumer Cyclical | Health |
52-Week High | $97.99 | $557.96 |
52-Week Low | $61.49 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $20.78B | $117.11B |
Dividend Yield | 1.08% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Somnigroup International (SGI) trades at $62.87, up 0.75% with neutral technical signals. The company shows strong profitability with 44.24% gross margins and has beaten earnings estimates for three consecutive quarters. Recent acquisition of Leggett & Platt enhances vertical integration with $75M synergy target. Analyst consensus is strongly bullish with 91% buy ratings and $94.50 price target, representing 50% upside potential from current levels.
SGI presents compelling growth prospects through strategic acquisitions and operational efficiencies, though faces margin pressures in weak bedding markets. The stock trades at reasonable valuations (P/E 24.85) with improving cash flow trends expected in 2026. Key risks include integration execution and market competition, but strong institutional interest and insider buying support the bullish case.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Somnigroup International Inc. Common Stock
Somnigroup International Inc. (formerly Tempur Sealy International) is a bedding and sleep-products company that designs, manufactures, distributes, and retails mattresses and related products. It operates through Tempur Sealy North America, Tempur Sealy International, and Mattress Firm, with brands including Tempur-Pedic, Sealy, Stearns & Foster, and Mattress Firm.
Read more on SGI →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
